



Tuberculosis Diagnostic, Treatments and Vaccines Research

Guest Editor:

Dr. Machelart Arnaud

Institut Pasteur de Lille, Centre
d'Infection et d'Immunité de Lille,
Université de Lille, CNRS
UMR9017, INSERM U1019, CHU
Lille, 59000 Lille, France

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

BCG (Bacillus Calmette-Guérin) remains the only effective vaccine against tuberculosis. Its discovery early in the 20th century allowed a drastic reduction in children mortalities. However, the vaccine has been shown to provide variable protection in adults against pulmonary tuberculosis. Novel and more effective strategies, including new vaccines or different use of BCG, are now essential to reduce the prevalence of the disease and foresee its eradication.

TB diagnosis is particularly difficult in immuno-compromised individuals or children. In this regard, the latest WHO report highlights improvements in TB diagnostics and shortening the time to initiate appropriate treatment as key priorities.

For this Special Issue of *Vaccines*, we kindly invite authors to submit an original research article or a review focusing on the recent advances to diagnose, prevent or treat TB. Potential topics could include (but are not limited to): new treatment strategies, vaccine studies, or the setting up of a new diagnostic test.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)